Affimed Delays Filing of 2024 Yearly Report

Affimed ( (AFMD) ) has released a notification of late filing.

Affimed N.V. has announced a delay in filing its Form 20-F (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the company’s need to enhance its liquidity position to ensure it can operate as a going concern for at least twelve months from the expected issuance date of the Form 20-F. The company is actively engaging with potential investors and partners to raise additional capital but cannot guarantee success. Affimed anticipates filing the Form 20-F as soon as practicable, though it may not meet the fifteen-day extension deadline. Preliminary financial estimates suggest cash reserves of approximately €13.0 million, sufficient to fund operations until the end of Q2 2025, a revision from the previous guidance of Q4 2025. The company does not expect significant changes in financial results from the previous year. The notification was signed by CEO Shawn Leland, who emphasized ongoing efforts to comply with regulatory requirements.

Spark’s Take on AFMD Stock

According to Spark, TipRanks’ AI Analyst, AFMD is a Neutral.

Affimed’s overall stock score reflects its financial struggles, with declining revenue and increasing losses being major concerns. The stock is technically weak, and the valuation is challenging due to negative earnings. Positive aspects from the earnings call, such as strategic progress in clinical trials and reduced losses, provide some optimism but are outweighed by financial and operational challenges.

To see Spark’s full report on AFMD stock, click here.

More about Affimed

YTD Price Performance: -26.30%

Average Trading Volume: 98,569

Technical Sentiment Signal: Buy

Current Market Cap: $15.15M

For an in-depth examination of AFMD stock, go to TipRanks’ Stock Analysis page.